Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 233-237

  Seifert Held, Thomas ^a   Pekar, Thomas ^a   Gattringer, Thomas ^a   Simmet, Nicole E ^a   Scharnagl, Hubert ^a   Stojakovic, Tatjana ^a   Fazekas, Franz ^a   Storch, Maria K ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cerebral ischemia; Dkk 1; Stroke

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; WNT PROTEIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANKIN SCALE; STROKE PATIENT; SYMPTOM; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052272778     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.015     Document Type: Article

References (30)

1. Sidow A. Diversification of the Wnt gene family on the ancestral lineage of vertebrates. Proc Natl Acad Sci U S A 1992, 89(11):5098-5102.
2. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004, 5(9):691-701.
3. Kawano Y., Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116(Pt 13):2627-2634.
4. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25(57):7469-7481.
5. Ueland T., Otterdal K., Lekva T., et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29(8):1228-1234.
6. Perez Castrillon J.L., San Miguel A., Vega G., et al. Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin. Int J Cardiol 2010, 145(1):164-165.
7. 2 levels. J Biol Chem 2011, 286(20):17649-17657.
8. Cappuccio I., Calderone A., Busceti C.L., et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci 2005, 25(10):2647-2657.
9. Mastroiacovo F., Busceti C.L., Biagioni F., et al. Induction of the Wnt antagonist Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab 2009, 29(2):264-276.
10. Rosi M.C., Luccarini I., Grossi C., et al. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem 2010, 112(6):1539-1551.
11. Caricasole A., Copani A., Caraci F., et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 2004, 24(26):6021-6027.
12. Feigin V.L., Lawes C.M., Bennett D.A., Anderson C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003, 2(1):43-53.
13. Brott T., Adams H.P., Olinger C.P., et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989, 20(7):864-870.
14. van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J., van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988, 19(5):604-607.
15. Quinn T.J., Dawson J., Walters M.R., Lees K.R. Functional outcome measures in contemporary stroke trials. Int J Stroke 2009, 4(3):200-205.
16. Janssen P.M., Visser N.A., Dorhout Mees S.M., Klijn C.J., Algra A., Rinkel G.J. Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis 2010, 29(2):137-139.
17. Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991, 337(8756):1521-1526.
18. Ay H., Benner T., Arsava E.M., et al. A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system. Stroke 2007, 38(11):2979-2984.
19. Arsava E.M., Ballabio E., Benner T., et al. The Causative Classification of Stroke system: an international reliability and optimization study. Neurology 2010, 75(14):1277-1284.
20. Voorzanger-Rousselot N., Goehrig D., Facon T., Clezardin P., Garnero P. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol 2009, 145(2):264-266.
21. Kammersgaard L.P., Jorgensen H.S., Nakayama H., Reith J., Raaschou H.O., Olsen T.S. Leukocytosis in acute stroke: relation to initial stroke severity, infarct size, and outcome: the Copenhagen Stroke Study. J Stroke Cerebrovasc Dis 1999, 8(4):259-263.
22. Sondergaard T.E., Pedersen P.T., Andersen T.L., et al. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 2009, 27(1):17-22.
23. Katan M., Fluri F., Morgenthaler N.G., et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009, 66(6):799-808.
24. Katan M., Fluri F., Schuetz P., et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010, 56(13):1045-1053.
25. Ferrari J., Knoflach M., Kiechl S., et al. Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry. Stroke 2010, 41(9):2001-2004.
26. Medinger M., Tzankov A., Kern J., et al. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Thromb Haemost 2011, 105(1):72-80.
27. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653(1):1-24.
28. Qian J., Xie J., Hong S., et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007, 110(5):1587-1594.
29. Choi Y., Arron J.R., Townsend M.J. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5(10):543-548.
30. Fulciniti M., Tassone P., Hideshima T., et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114(2):371-379.